The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•31 March 2026•

1 min read

Theravance Biopharma Settles YUPELRI Patent Dispute, Securing Exclusivity Until 2039

Key Facts

1Theravance Biopharma reached a settlement with Mankind Pharma regarding patent litigation for YUPELRI inhalation solution.

2The agreement allows Mankind Pharma to launch a generic version of the drug in the U.S. starting April 23, 2039.

3The settlement ensures long-term exclusivity for Theravance and removes legal risks associated with the litigation.

Create Free Account

Theravance Biopharma (TBPH) has successfully reached a settlement agreement with Mankind Pharma regarding patent litigation for its YUPELRI inhalation solution. Under the terms of the agreement, Mankind Pharma is permitted to launch a generic version of the drug in the United States starting April 23, 2039. This settlement is a significant milestone for Theravance, as it ensures long-term commercial exclusivity for one of its key products. By resolving these legal uncertainties, the company effectively removes the risks associated with protracted litigation and potential early generic competition. The deal provides much-needed revenue visibility for TBPH, strengthening the company's valuation and long-term strategic outlook. Market analysts view this development as a positive step in protecting the company's intellectual property and securing its future cash flows.